Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
09 mai 2024 16h05 HE
|
Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected Q3 2024 - - Strengthened Management Team and Board of Directors with Two Key Additions -- Management to Host Webcast...
Corza Medical Named “Best Overall MedTech Company” in 8th Annual MedTech Breakthrough Awards Program
09 mai 2024 10h30 HE
|
Corza Medical Inc.
Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies WESTWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corza Medical...
Global Cell and Gene Therapy in Ophthalmology Research Report 2024: Market Anticipated to Soar with Projected CAGR Growth of 50.8% by 2029
09 mai 2024 09h43 HE
|
Research and Markets
Dublin, May 09, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapies in Ophthalmology" report has been added to ResearchAndMarkets.com's offering.Despite the high cost of therapies, linked to the...
Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference
08 mai 2024 16h15 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
EyeDNA Therapeutics Announces Positive 24-month Data Presented at ARVO from Ongoing Phase I/II Trial of HORA-PDE6b Gene Therapy in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
07 mai 2024 03h00 HE
|
Coave Therapeutics
Clinically meaningful benefit in visual functions and good safety profile of HORA-PDE6b is confirmed at 24-month follow-up Phase I/II results will be discussed with US and...
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
03 mai 2024 07h30 HE
|
Ocugen
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
02 mai 2024 07h15 HE
|
Ocugen
MALVERN, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Patients During the ARVO 2024 Annual Meeting May 5-9
01 mai 2024 09h00 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Patients During the ARVO 2024 Annual Meeting May 5-9
Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
01 mai 2024 07h30 HE
|
Atsena Therapeutics
Subretinal injection of ATSN-201 was well tolerated in all patients in the first cohort with extensive resolution of schisis observed in two patients Provides evidence that AAV.SPR spreads laterally...
Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024
30 avr. 2024 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...